Myovant Sciences Quick Ratio 2017-2022 | MYOV

Historical quick ratio values for Myovant Sciences (MYOV) over the last 10 years.
Myovant Sciences Quick Ratio Historical Data
Date Current Assets - Inventory Current Liabilities Quick Ratio
2022-03-31 $0.48B $0.25B 1.92
2021-12-31 $0.57B $0.27B 2.11
2021-09-30 $0.65B $0.27B 2.42
2021-06-30 $0.70B $0.31B 2.27
2021-03-31 $0.70B $0.28B 2.50
2020-12-31 $0.00B $0.25B 0.00
2020-09-30 $0.00B $0.07B 0.00
2020-06-30 $0.00B $0.05B 0.00
2020-03-31 $0.00B $0.09B 0.00
2019-12-31 $0.00B $0.05B 0.00
2019-09-30 $0.00B $0.06B 0.00
2019-06-30 $0.00B $0.07B 0.00
2019-03-31 $0.00B $0.07B 0.00
2018-12-31 $0.00B $0.06B 0.00
2018-09-30 $0.00B $0.05B 0.00
2018-06-30 $0.00B $0.05B 0.00
2018-03-31 $0.00B $0.04B 0.00
2017-12-31 $0.00B $0.03B 0.00
2017-09-30 $0.00B $0.02B 0.00
2017-06-30 $0.00B $0.02B 0.00
2017-03-31 $0.00B $0.02B 0.00
2016-12-31 $0.00B $0.01B 0.00
2016-09-30 $0.00B $0.01B 0.00
2016-06-30 $0.00B $0.00B 0.00
2016-03-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.236B $0.231B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00